Imanis Life Sciences Announces Improvements and Increased Capacity of IMMUNO-COV™, a First-in-Class Neutralizing Antibody Test for COVID-19
19 nov. 2020 09h00 HE
|
Imanis Life Sciences, LLC
ROCHESTER, Minn., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Imanis Life Sciences, LLC (“Imanis” or “The Company”) announced today that it has completed validation of its latest improved IMMUNO-COVTM...
TeneoFour’s CD38 Inhibitor Rejuvenates Energy Metabolism of Aged Animals
16 nov. 2020 11h00 HE
|
TeneoBio, Inc
NEWARK, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoFour, Inc. announced today a Nature Metabolism publication...
Aptean Launches New, First-to-Market Antibody Search Solution to Support Biologics Research and Development
26 oct. 2020 09h00 HE
|
Aptean Inc.
ALPHARETTA, Ga., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Today, Aptean, a global provider of mission-critical enterprise software solutions, announced the release of a new solution designed to help...
Teneobio Announces US FDA Clearance of Investigational New Drug Application for TNB-486 and the Initiation of Phase I Clinical Studies in Patients with B-cell Malignancies
01 oct. 2020 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoTwo, Inc. announced today that their investigational new drug application (IND) for TNB-486, a bispecific...
Sorrento Releases Preclinical Data for STI-1499 (COVI-Guard™) and STI-2020 (COVI-AMG™), Potent Neutralizing Antibodies Against SARS-CoV-2
28 sept. 2020 23h59 HE
|
Sorrento Therapeutics, Inc.
In preclinical studies, both STI-1499 and STI-2020 demonstrated potent neutralizing activity against SARS-CoV-2 virus isolates, including the emerging Spike D614G variant virus.Both STI-1499 and...
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trial of STI-1499 (COVI-GUARD) Neutralizing Antibody in COVID-19 Positive Patients
16 sept. 2020 21h30 HE
|
Sorrento Therapeutics, Inc.
Phase 1 clinical trial for STI-1499 (COVI-GUARD™) in hospitalized COVID-19 patients has received FDA notice that it may proceed with patient enrollment.The initial trial is expected to enroll rapidly...
ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01
10 sept. 2020 05h46 HE
|
ImCheck Therapeutics SAS
ImCheck Achieves Initial Positive Independent Safety Reviewand Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01 Company Receives FDA Approval for US IND ...
Monopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19
09 sept. 2020 08h30 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., BELOIT, Wis. and TYLER, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing...
Precipio Announces a Shareholder Call to Discuss its COVID-19 Progress and Future Plans
04 sept. 2020 09h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting a shareholder call to address questions related to the...
Aegis Sciences Corporation announces it has been awarded $6.6 million NIH grant to rapidly expand COVID-19 Test Capacity
02 sept. 2020 11h05 HE
|
Aegis Sciences Corporation
NASHVILLE, Tenn., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative medication compliance testing and consulting...